Home
Drugs
Targets
Pathways
Ontologies
Cyp450s
Adv.search
Help/FAQ

Drug-Target Interaction

Drug

show drug details
PubChem ID:3690
Structure:
Synonyms:
(+)-ifosfamid
(+)-ifosphamide
(+)-tetrahydro-n,3-bis(2-chloroethyl)-2h-1,3,2-oxazaphosphorin-2-amine 2-oxide
(+-)-Ifosfamid
(+-)-Ifosphamide
(+-)-Tetrahydro-N,3-bis(2-chloroethyl)-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
(D,L)-Ifosfamide
(R,S)-Ifosphamide
(R,S)-N,3-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide
1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-, 2-oxide
2,3-(N,N(sup 1)-Bis(2-chloroethyl)diamido)-1,3,2-oxazaphosphoridinoxyd
2,3-N,N(sup 1)-Bis(2-chloroethyl)diamido-1,3,2-oxazaphosphoridinoxy-
2,3-N,N(sup 1)-Bis(2-chloroethyl)diamido-1,3,2-oxazaphosphoridinoxyd
2H-1,3,2-Oxazaphosphorin-2-amine, N,3-bis( 2-chloroethyl)tetrahydro-, 2-oxide
2H-1,3,2-Oxazaphosphorin-2-amine, N,3-bis(2-chloroethyl)tetrahydro-,
2H-1,3,2-Oxazaphosphorin-2-amine, N,3-bis(2-chloroethyl)tetrahydro-, 2-oxide
2h-1,3,2-oxazaphosphorin-2-amine, tetrahydro-n,3-bis(2-chloroethyl)-, 2-oxide, (+)-
2H-1,3,2-Oxazaphosphorin-2-amine, tetrahydro-N,3-bis(2-chloroethyl)-, 2-oxide, (+-)-
2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide
2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-, 2-oxide (8CI)
2H-1,3,2-Oxazaphosphorine, 3-(2-chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-, 2-oxide
3-(2-Chloroethyl)-2-((2-chloroethyl)amino)perhydro-2H-1,3,2-oxazaphosphorine oxide
3-(2-Chloroethyl)-2-((2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide
3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,3,2-oxazaphosphorine oxide
3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,3,2-oxazaphosphorineoxide
3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2- oxide
3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide
36341-88-5
3778-73-2
84711-20-6
A 4942
AB00513932
AIDS-126436
AIDS126436
ASTA Z 4942
BPBio1_000865
BRN 0611835
BSPBio_000785
C07047
C7H15Cl2N2O2P
CAS-3778-73-2
CCRIS 352
Cyfos
D00343
D007069
DB01181
DRG-0207
EINECS 223-237-3
Holoxan
Holoxan 1000
HSDB 7023
I-Phosphamide
Ifex
Ifex (TN)
IFEX/MESNEX KIT
Ifosamide
Ifosfamid
Ifosfamida
Ifosfamida [INN-Spanish]
Ifosfamide
Ifosfamide (JAN/USP/INN)
Ifosfamide Sterile
Ifosfamide [USAN:BAN:INN:JAN]
Ifosfamide [USAN:INN:BAN:JAN]
IFOSFAMIDE/MESNA KIT
Ifosfamidum
Ifosfamidum [INN-Latin]
Ifsofamide
Iphosphamid
Iphosphamid(e)
Iphosphamide
Iso Endoxan
Iso-Endoxan
Isoendoxan
Isofosfamide
Isophosphamide
LS-102
LS-99799
Mitoxana
MJF 9325
MJF-9325
MLS002154021
N,3-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
N,3-bis(2-chloroethyl)-2-oxo-1-oxa-3-aza-2$l^{5}-phosphacyclohexan-2-amine
N,3-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
N,N-Bis(beta-chloroethyl)-amino-N',O-propylene-phosphoric acid ester diamide
N-(2-Chloraethyl)-N'-(2-chloraethyl)-N',O-propylen-phosphorsaureester-diamid [German]
N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylen ephosphoric acid diamide
N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylene phosphoric acid ester diamide
N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylenephosphoric acid diamide
N-(2-Chloroethyl)-N'-(2-chloroethyl)-N',O-propylenephosphoric acid ester diamide
N-(2-Chloroethyl)-N-(3-(2-chloroethyl)-2-oxido-1,3,2-oxazaphosphinan-2-yl)amine
Naxamide
NCGC00016639-01
NCGC00179435-01
NCI-C01638
NCI60_000233
NSC 109,724
NSC 109724
NSC-109,724
NSC-109724
NSC109,724
NSC109724
Prestwick0_000833
Prestwick1_000833
Prestwick2_000833
Prestwick3_000833
SMR001233348
SPBio_002706
WLN: T6NPOTJ AM2G BO B2G
Z 4942
Z-4942
Z4942
{3-(2-Chloroethyl)-2-[(2-
{3-(2-Chloroethyl)-2-[(2-chloroethyl)amino]perhydro-2H-1,3,} 2-oxazaphosphorine oxide
ATC-Codes:
Side-Effects:
Side-EffectFrequency
auditory hallucinations0
siadh0
nephrogenic diabetes insipidus0
pulmonary fibrosis0
dysuria0
pyrexia of unknown origin0
encephalopathy0
confusion0
seizures0
peripheral neuropathy0
vomiting0
renal tubular acidosis0
asthenia0
dermatitis0
hypotension0
nausea0
thrombophlebitis0
stupor0
allergic reaction0
leukopenia0
cystitis0
infection0
somnolence0
polyneuropathy0
depressive psychosis0
hallucinations0
interstitial pneumonitis0
blurred vision0
coma0
alopecia0
anorexia0
acidosis0
constitutional symptoms0
arrhythmia0
hypersensitivity0
hematemesis0
amenorrhea0
metabolic acidosis0
heart failure0
proteinuria0
hyperaminoaciduria0
pancreatitis0
fever0
hematuria0
hyperpigmentation0
agitation0
generalized seizures0
rickets0
thrombocytopenia0
nephropathy0
arteriosclerosis0
anemia0
renal tumor0
urinary frequency0
encephalitis0
renal failure0
constipation0
dizziness0
stomatitis0
pulmonary edema0
hypertension0
urinary incontinence0
neutropenia0
hemorrhage0
diarrhea0

Target

show target details
Uniprot ID:CP2CI_HUMAN
Synonyms:
CYPIIC18
Cytochrome P450 2C18
P450-6B/29C
EC-Numbers:1.14.14.1
Organism:Homo sapiens
Human
PDB IDs:2H6P
Structure:
2H6P

Binding Affinities:

Ki: Kd:Ic 50:Ec50/Ic50:
----

References:

10348794
Development of a substrate-activity based approach to identify the major human liver P-450 catalysts of cyclophosphamide and ifosfamide activation based on cDNA-expressed activities and liver microsomal P-450 profiles.. P Roy; L J Yu; C L Crespi; D J Waxman (1999) Drug metabolism and disposition: the biological fate of chemicals display abstract
The contributions of specific human liver cytochrome P-450 (CYP) enzymes to the activation, via 4-hydroxylation, of the oxazaphosphorine anticancer prodrugs cyclophosphamide (CPA) and ifosfamide (IFA) were investigated. Analysis of a panel of 15 human P-450 cDNAs expressed in human lymphoblasts and/or baculovirus-infected insect cells (Supersomes) demonstrated that CYPs 2A6, 2B6, 3A4, 3A5, and three CYP2C enzymes (2C9, 2C18, 2C19) exhibited significant oxazaphosphorine 4-hydroxylase activity, with 2B6 and 3A4 displaying the highest activity toward CPA and IFA, respectively. CYP2B6 metabolized CPA at a approximately 16-fold higher in vitro intrinsic clearance (apparent Vmax/Km) than IFA, whereas 3A4 demonstrated approximately 2-fold higher Vmax/Km toward IFA. A relative substrate-activity factor (RSF)-based method was developed to calculate the contributions of individual P-450s to total human liver microsomal metabolism based on cDNA-expressed P-450 activity data and measurements of the liver microsomal activity of each P-450 form. Using this method, excellent correlations were obtained when comparing measured versus predicted (calculated) microsomal 4-hydroxylase activities for both CPA (r = 0. 96, p